192 related articles for article (PubMed ID: 30874871)
1. Is it required to routinely check fibrinogen level in patients with rheumatic diseases on tocilizumab? Case-based review.
Üsküdar Cansu D; Demirtaş E; Andiç N; Üsküdar Teke H; Korkmaz C
Rheumatol Int; 2019 Apr; 39(4):743-750. PubMed ID: 30874871
[TBL] [Abstract][Full Text] [Related]
2. Clinical observation of hypofibrinogenemia induced by the treatment of tocilizumab in rheumatic diseases and exploration of risk factor for hypofibrinogenemia.
An Q; Ma R; Yuan D; Huang J; Luo J; Wang Y; Pan Y; Wang P; Lv X; Pu D; He L
Clin Rheumatol; 2024 May; 43(5):1491-1501. PubMed ID: 38494557
[TBL] [Abstract][Full Text] [Related]
3. Tocilizumab-induced hypofibrinogenemia in patients with systemic-onset juvenile idiopathic arthritis.
He T; Ling J; Yang J
Sci Rep; 2023 Jun; 13(1):9050. PubMed ID: 37270663
[TBL] [Abstract][Full Text] [Related]
4. Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice.
Calderón-Goercke M; Loricera J; Aldasoro V; Castañeda S; Villa I; Humbría A; Moriano C; Romero-Yuste S; Narváez J; Gómez-Arango C; Pérez-Pampín E; Melero R; Becerra-Fernández E; Revenga M; Álvarez-Rivas N; Galisteo C; Sivera F; Olivé-Marqués A; Álvarez Del Buergo M; Marena-Rojas L; Fernández-López C; Navarro F; Raya E; Galindez-Agirregoikoa E; Arca B; Solans-Laqué R; Conesa A; Hidalgo C; Vázquez C; Román-Ivorra JA; Lluch P; Manrique-Arija S; Vela P; De Miguel E; Torres-Martín C; Nieto JC; Ordas-Calvo C; Salgado-Pérez E; Luna-Gomez C; Toyos-Sáenz de Miera FJ; Fernández-Llanio N; García A; Larena C; Palmou-Fontana N; Calvo-Río V; Prieto-Peña D; González-Vela C; Corrales A; Varela-García M; Aurrecoechea E; Dos Santos R; García-Manzanares Á; Ortego N; Fernández S; Ortiz-Sanjuán F; Corteguera M; Hernández JL; González-Gay MÁ; Blanco R
Semin Arthritis Rheum; 2019 Aug; 49(1):126-135. PubMed ID: 30655091
[TBL] [Abstract][Full Text] [Related]
5. Tocilizumab-induced hypofibrinogenemia: A report of 7 cases.
Martis N; Chirio D; Queyrel-Moranne V; Zenut MC; Rocher F; Fuzibet JG
Joint Bone Spine; 2017 May; 84(3):369-370. PubMed ID: 27324602
[No Abstract] [Full Text] [Related]
6. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients.
Loricera J; Blanco R; Hernández JL; Castañeda S; Mera A; Pérez-Pampín E; Peiró E; Humbría A; Calvo-Alén J; Aurrecoechea E; Narváez J; Sánchez-Andrade A; Vela P; Díez E; Mata C; Lluch P; Moll C; Hernández Í; Calvo-Río V; Ortiz-Sanjuán F; González-Vela C; Pina T; González-Gay MÁ
Semin Arthritis Rheum; 2015 Jun; 44(6):717-23. PubMed ID: 25697557
[TBL] [Abstract][Full Text] [Related]
7. Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis.
de Boysson H; Le Besnerais M; Blaison F; Daumas A; Jarrot PA; Perrin F; Tieulié N; Maria A; Duffau P; Gombert B; Samson M; Espitia O; Lambert M; Mékinian A; Aouba A;
Arthritis Res Ther; 2021 May; 23(1):143. PubMed ID: 34011407
[TBL] [Abstract][Full Text] [Related]
8. Intravenous tocilizumab for the treatment of giant cell arteritis: a phase Ib dose-ranging pharmacokinetic bridging study.
Schmitt C; Brockwell L; Giraudon M; Zucchetto M; Christ L; Bannert B; Daikeler T; Villiger PM
Arthritis Res Ther; 2022 Jun; 24(1):133. PubMed ID: 35659282
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.
Unizony S; Arias-Urdaneta L; Miloslavsky E; Arvikar S; Khosroshahi A; Keroack B; Stone JR; Stone JH
Arthritis Care Res (Hoboken); 2012 Nov; 64(11):1720-9. PubMed ID: 22674883
[TBL] [Abstract][Full Text] [Related]
10. Tocilizumab in Giant Cell Arteritis: A Multicenter Retrospective Study of 34 Patients.
Régent A; Redeker S; Deroux A; Kieffer P; Ly KH; Dougados M; Liozon E; Larroche C; Guillevin L; Bouillet L; Espitia O; Costedoat-Chalumeau N; Soubrier M; Brihaye B; Lifermann F; Lefevre G; Puéchal X; Mouthon L; Toussirot E;
J Rheumatol; 2016 Aug; 43(8):1547-52. PubMed ID: 27182063
[TBL] [Abstract][Full Text] [Related]
11. Glucocorticoid Dosages and Acute-Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab.
Stone JH; Tuckwell K; Dimonaco S; Klearman M; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Schulze-Koops H; Schett G; Spiera R; Unizony SH; Collinson N
Arthritis Rheumatol; 2019 Aug; 71(8):1329-1338. PubMed ID: 30835950
[TBL] [Abstract][Full Text] [Related]
12. Tocilizumab for the treatment of giant cell arteritis.
Schirmer M; Muratore F; Salvarani C
Expert Rev Clin Immunol; 2018 May; 14(5):339-349. PubMed ID: 29676602
[TBL] [Abstract][Full Text] [Related]
13. Tocilizumab, an effective treatment for relapsing giant cell arteritis.
Oliveira F; Butendieck RR; Ginsburg WW; Parikh K; Abril A
Clin Exp Rheumatol; 2014; 32(3 Suppl 82):S76-8. PubMed ID: 24854376
[TBL] [Abstract][Full Text] [Related]
14. Tocilizumab in giant cell arteritis: an update for the clinician.
Ford JA; Gewurz D; Gewurz-Singer O
Curr Opin Rheumatol; 2023 May; 35(3):135-140. PubMed ID: 36912060
[TBL] [Abstract][Full Text] [Related]
15. Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients.
Calderón-Goercke M; Loricera J; Moriano C; Castañeda S; Narváez J; Aldasoro V; Maiz O; Melero R; Villa JI; Vela P; Romero-Yuste S; Callejas JL; de Miguel E; Galíndez-Agirregoikoa E; Sivera F; Fernández-López JC; Galisteo C; Ferraz-Amaro I; Sanchéz-Martín J; Sánchez-Bilbao L; González-Gay MA; Hernández JL; Blanco R;
Clin Exp Rheumatol; 2023 Apr; 41(4):829-836. PubMed ID: 36377586
[TBL] [Abstract][Full Text] [Related]
16. Pathophysiology of large vessel vasculitis and utility of interleukin-6 inhibition therapy.
Yoshifuji H
Mod Rheumatol; 2019 Mar; 29(2):287-293. PubMed ID: 30427262
[TBL] [Abstract][Full Text] [Related]
17. Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis - case report.
Butryn M; Mewes S; Feist E; Beuing O; Müller C; Neumann J
BMC Neurol; 2021 Jun; 21(1):228. PubMed ID: 34157987
[TBL] [Abstract][Full Text] [Related]
18. Tocilizumab in Giant Cell Arteritis: A Real-Life Retrospective Study.
Vitiello G; Orsi Battaglini C; Carli G; Radice A; Matucci A; Vultaggio A; Olianti C; Parronchi P; Maggi E; Cammelli D
Angiology; 2018 Oct; 69(9):763-769. PubMed ID: 29343075
[TBL] [Abstract][Full Text] [Related]
19. New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension.
Stone JH; Spotswood H; Unizony SH; Aringer M; Blockmans D; Brouwer E; Cid MC; Dasgupta B; Rech J; Salvarani C; Spiera R; Bao M
Rheumatology (Oxford); 2022 Jul; 61(7):2915-2922. PubMed ID: 34718434
[TBL] [Abstract][Full Text] [Related]
20. Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study.
Samson M; Devilliers H; Ly KH; Maurier F; Bienvenu B; Terrier B; Charles P; Guillevin L; Besancenot JF; Liozon E; Fauchais AL; Loffroy R; Binquet C; Audia S; Seror R; Mariette X; Bonnotte B
Eur J Intern Med; 2018 Nov; 57():96-104. PubMed ID: 30054122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
